Virbac S.A.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Virbac S.A. (VRBCF) manufactures and markets a comprehensive range of veterinary pharmaceuticals, vaccines, and services dedicated exclusively to animal health for companion animals and livestock; its core offerings include internal and external parasiticides such as collars and pipettes, antibiotics, anti-inflammatory drugs, dermatology products, dental hygiene solutions, diagnostic tests, nutrition and petfood, reproductive aids, anesthesia products, geriatrics treatments, electronic identification systems for pets, horses and exotic animals, and specialized solutions for aquaculture; the company serves veterinarians, farmers, and pet owners worldwide. Founded in 1968 by veterinarian Pierre-Richard Dick and headquartered in Carros, France, Virbac operates in more than 100 countries through 35 sales subsidiaries and production facilities in 10 countries including France, the United States, Mexico, Brazil, and Vietnam, with eight research and development centers across the United States, Mexico, Chile, Uruguay, France, Vietnam, Taiwan, and Australia; it employs approximately 6,400 people and generates nearly 60% of revenues outside France, with geographic sales distributed as Europe (40.8%), Latin America (15.9%), North America (13%), India/Africa/Middle East (12.5%), East Asia (10.1%), and Pacific (7.7%). Recent strategic expansions include the November 2023 acquisition of a majority stake in Globion, an Indian poultry vaccines specialist to strengthen its avian portfolio and leadership in India's animal health market; the April 2024 completion of the €280 million acquisition of Sasaeah from ORIX Corporation, establishing leadership in Japan's farm animal vaccines particularly cattle and adding pharmaceutical products across major species with production in Japan and Vietnam; and the December 2024 acquisition of Mopsan, its Turkish distributor of petfood and companion animal health products; additionally in April 2025 Virbac licensed therapeutic antibodies from MabGenesis for canine diseases, supporting ongoing innovation amid strong 2024 revenue growth of 13.6% at constant rates to €1,397.5 million driven by these acquisitions and organic performance.
Virbac : Declaration of the number of shares and voting rights 04/2026
Virbac : Public release of Virbac Annual Report at 31 December 2025.
Virbac: strong Q1 2026 growth of +7.7% at CERS, driven by double-digit growth of our priority Supercharge4 platforms
Virbac : Declaration of the number of shares and voting rights 03/2026
Virbac SA (VRBCF) Q4 2025 Earnings Call Transcript
Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2025
Virbac: 2025 annual results
Virbac : Declaration of the number of shares and voting rights 02/2026
Virbac : Declaration of the number of shares and voting rights 01/2026
Virbac : Declaration of the number of shares and voting rights 11/2025
VIRBAC Announces Third Quarter 2025 Sales
Virbac SA (VRBCF) Q2 2025 Earnings Call Transcript
Virbac: 2025 Half-year results
Virbac : Public release of the Half-Year Financial Report at 30 June 2025.
Virbac : Half-yearly financial report 2025
Virbac:: Paul Martingell's compensation terms
Virbac: in the first half of 2025, revenue recorded solid growth of +5.6% at constant exchange rates and scope of consolidation
VIRBAC: Paul Martingell is appointed chief executive officer of Virbac, effective September 1, 2025
Virbac : Public release of Virbac Annual Report at 31 December 2024
Virbac: In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope